New weapon tested against deadly recurrent brain tumors
NCT ID NCT02303678
Summary
This early-stage study tested a new drug called D2C7-IT in adults whose aggressive brain cancer (malignant glioma) had returned. The main goal was to find the safest dose by delivering the drug directly into the tumor through tiny catheters over 72 hours. Researchers enrolled 81 patients to monitor side effects and gather initial data on how the treatment might work.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Preston Robert Tisch Brain Tumor Center at Duke
Durham, North Carolina, 27710, United States
Conditions
Explore the condition pages connected to this study.